Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials

Christian J Wiedermann1*, Stefan Dunzendorfer2, Luigi U Gaioni1, Francesco Zaraca3, Michael Joannidis2

Abstract

Introduction: It has been hypothesized that hyperoncotic colloids might contribute to acute kidney injury (AKI). However, the validity of this hypothesis remains unclear.

Methods: A meta-analysis was conducted of randomized controlled trials evaluating AKI after infusion of hyperoncotic albumin and hydroxyethyl starch (HES) solutions. Mortality was a secondary endpoint. Eligible trials were sought by multiple methods, and the pooled odds ratios (OR) for AKI and death and 95% confidence intervals (CI) were computed under a random effects model.

Results: Eleven randomized trials with a total of 1220 patients were included: 7 evaluating hyperoncotic albumin and 4 hyperoncotic HES. Clinical indications were ascites, surgery, sepsis and spontaneous bacterial peritonitis. Hyperoncotic albumin decreased the odds of AKI by 76% (OR, 0.24; CI, 0.12-0.48; \(P < 0.0001\)), while hyperoncotic HES increased those odds by 92% (OR, 1.92; CI, 1.31-2.81; \(P = 0.0008\)). Parallel effects on mortality were observed, with hyperoncotic albumin reducing the odds of death by 48% (OR, 0.52; CI, 0.28-0.95; \(P = 0.035\)) and hyperoncotic HES raising those odds by 41% (OR, 1.41; CI, 1.01-1.96; \(P = 0.043\)).

Conclusions: This meta-analysis does not support the hypothesis that hyperoncotic colloid solutions per se injure the kidney. Renal effects appear instead to be colloid-specific, with albumin displaying renoprotection and HES showing nephrotoxicity.

Introduction

The potential for beneficial or deleterious renal effects is a key consideration in the selection and use of colloid solutions for clinical fluid management. In a systematic review, albumin was found to protect the kidney, whereas the carbohydrate-based artificial colloids hydroxyethyl starch (HES) and dextran were frequently associated with acute kidney injury (AKI) [1]. Confirmation with respect to the negative effects of HES has been provided by two recent meta-analyses of randomized trials showing increased incidence of acute renal failure (ARF) [2] and need for renal replacement therapy (RRT) [3] in patients receiving HES and by a systematic review [4].

Renal effects might be influenced not only by the specific properties of the particular colloid molecule but also by higher colloid osmotic pressure (COP) [5], assuming that increased COP decreases effective glomerular filtration pressure and thus glomerular filtration rate antagonizing hydrostatic pressure [6]. Colloid solutions can be classified as hypo-oncotic, iso-oncotic, or hyperoncotic according to whether their COP is less than, similar to, or greater than that of plasma, respectively. COP is strongly dependent upon the concentration of colloid in the solution [7]. Thus, 4% to 5% albumin is hypo-oncotic, whereas 20% to 25% albumin is hyperoncotic [8-11]. Similarly, 6% HES is iso-oncotic, whereas 10% HES is hyperoncotic [8,9,11,12]. Molecular weight and substitution show little if any effect on the COP of HES solutions [9,11].

With their capacity to draw interstitial fluid into the intravascular compartment, hyperoncotic solutions provide an attractive option for volume expansion because they are rapidly effective in a small infused volume and can serve to minimize edema [13]. However, in an analysis of data from the CRYstalloids or COlloids (CRYCO) study observational study of 1,013 intensive care unit patients, exposure to hyperoncotic solutions of...
either albumin or HES was associated with increased occurrence of AKI as compared with crystalloids or hypo-oncotic colloids [5]. That analysis suggests that hyperoncotic colloids per se might be harmful to the kidney. On the other hand, no adverse renal effects were evident in a multicenter study of 600 patients receiving hyperoncotic 25% albumin [14] or in a recent meta-analysis of 25 randomized trials (with a total of 1,485 patients) evaluating hyperoncotic albumin [13]. Moreover, in randomized trials, iso-oncotic 6% HES increased the incidence of ARF in patients with severe sepsis or septic shock [15] and the need for RRT after kidney transplantation [16]. In light of the conflicting data, investigators are uncertain about the renal effects of hyperoncotic colloids. The present meta-analysis of randomized trials was designed to test the hypothesis that hyperoncotic colloids per se increase the incidence of AKI.

Materials and methods

Endpoints

This meta-analysis addressed the question: does infusion of hyperoncotic 20% to 25% albumin or 10% HES to prevent or correct hypovolemia increase the risk of AKI as compared with crystalloid, hypo-oncotic 4% to 5% albumin, or no fluid? Mortality was a secondary endpoint.

Study selection

Parallel-group randomized controlled trials (RCTs) were eligible for inclusion if they evaluated the occurrence of AKI in patients receiving hyperoncotic solutions of 20% to 25% albumin or 10% HES for prevention or correction of hypovolemia. The control regimen could consist of crystalloid, hypo-oncotic 4% to 5% albumin, or no fluid? Mortality was a secondary endpoint.

Results

Included trials

The number of candidate RCTs identified and screened was 109 (Figure 1). Upon detailed evaluation of the candidates, 98 were excluded. The most common reasons
for exclusion were a non-hyperoncotic test colloid, an iso- or hyperoncotic colloid, a drug or procedure control, and an investigational design other than a parallel-group RCT. Eleven RCTs with a total of 1,220 patients fulfilled all eligibility criteria and were included in the meta-analysis [17-27]. All trials had been published. Three of the 11 included trials were reported in the 1980s and four each in the 1990s and 2000s (Table 1). Two trials were blinded and two were not, whereas the use of blinding was unspecified for the remaining seven trials. Allocation concealment was adequate in five trials and unspecified in six. The indication for volume expansion with colloid was treatment of ascites as an adjunct to paracentesis in three trials and to diuretics in one, surgery in three, and sepsis and spontaneous bacterial peritonitis in two each. One trial encompassed separate protocols for acute treatment of ascites in the hospital and subsequent long-term outpatient maintenance therapy [22]. Only the results from the acute treatment protocol were used in the meta-analysis. The median number of patients per trial was 72, and the interquartile range (IQR) was 32 to 116. More than 100 patients were evaluated in four trials, but only one trial involved over 200 patients. With 537 patients, that trial [25] was by far the largest included in the meta-analysis. Mean ages of patients in the trials were comparatively homogeneous. Whereas age averaged 49.1 years in one trial, the mean values in the other 10 trials fell within the relatively narrow range of 55.7 to 64.7 years. The median percentage of male patients in the included trials was 60% (IQR 60% to 65%). Seven trials evaluated hyperoncotic 20% to 25% albumin, and four trials evaluated hyperoncotic 10% HES. Control treatments were no colloid in seven trials, crystalloid in three, and hyponcotic colloid in one.

**Acute kidney injury**

The AKI diagnosis criteria adopted in four trials included an increase of 50% or more in serum creatinine or blood urea nitrogen (Table 1). The need for RRT was the criterion in three trials, whereas other or unspecified criteria were applied in two trials each. Across all 11 studies, 199 of 1,220 patients (16%) developed AKI (Figure 2). As shown in Figure 2, hyperoncotic albumin decreased the odds of AKI by 76% (OR 0.24, CI 0.12 to 0.48; P < 0.0001). Among the seven trials evaluating hyperoncotic albumin, there was no evidence of either heterogeneity (P = 0.81; I² = 0%) or publication (P = 0.74) bias with respect to the AKI endpoint. Hyperoncotic HES showed the opposite effect (Figure 2), increasing the odds of AKI by 92% (OR 1.92, CI 1.31 to 2.81; P = 0.0008). Neither heterogeneity (P = 0.89; I² = 0%) nor publication (P = 0.55) bias was detectable in the AKI data from the four trials of hyperoncotic HES.
The meta-analysis of RCTs did not support the hypothesis that hyperoncotic colloids per se are injurious to the kidney. It appeared that, within physiologic ranges, the specific properties of the colloid molecule rather than concentration are the major determinants of renal effects. According to our results, administration of hyperoncotic albumin was associated with reduced risk of AKI as well as with improved survival. By contrast, HES displayed nephrotoxicity and worsened survival.

Certain limitations of this meta-analysis should be noted. Criteria for diagnosing AKI were not standardized. Other than one surgery trial, all six other included trials of hyperoncotic albumin involved cirrhotic patients, whereas those evaluating hyperoncotic HES all concerned surgery or sepsis. Thus, the clinical settings for evaluation of the two hyperoncotic colloids were largely non-overlapping.
Six of the seven included trials evaluating hyperoncotic albumin involved cirrhotic patients. In all six of those trials, the observed reduction in the AKI incidence was less than in the seventh trial, which evaluated major abdominal surgery patients [17]. Extravascular fluid accumulation is a common complication of cirrhosis, which might be precipitated or exacerbated by hypo-oncotic fluid, and in five of the six included trials of cirrhotic patients, the selected control regimen consisted of no volume expander. The possibility could be entertained that volume expansion with a control fluid might have produced the same results as did hyperoncotic albumin in those trials. In one included trial [24], however, cirrhotic patients with ascites did receive saline as the control fluid. That group developed paracentesis-induced circulatory dysfunction with a frequency that was significantly higher (33.3%) than that of the patients allocated to hyperoncotic albumin (11.4%). Additionally, a randomized trial not included in this meta-analysis compared hyperoncotic 20% albumin with iso-oncotic 6% HES 200/0.5 in cirrhotic patients with spontaneous bacterial peritonitis [28]. Although the trial was not powered to assess AKI, the incidence of AKI was nevertheless lower in the hyperoncotic albumin group (OR 0.29, CI 0.03 to 3.12), and significant improvement in circulatory function was demonstrated in that group but not among the patients assigned to iso-oncotic HES.

The present meta-analysis is the first to investigate AKI specifically after infusion of hyperoncotic 10% HES. Prior systematic reviews and meta-analyses have not differentiated between iso-oncotic and hyperoncotic HES solutions [1-3,29]. Even in the CRYCO analysis, the designated hyperoncotic HES group did not actually receive hyperoncotic solutions exclusively [5]. Iso-oncotic 6% HES 130/0.4, for example, was among the solutions assigned to the CRYCO hyperoncotic HES group.

In three of the four included trials evaluating hyperoncotic HES, AKI was more frequent in the hyperoncotic HES group than the control group, and in all four of those trials, mortality was higher in hyperoncotic HES recipients. Nevertheless, the preponderance of the statistical power was derived from a single large trial [25], and it should be recognized that the conclusions of the meta-analysis regarding hyperoncotic HES rest primarily on that trial. If that trial were to be excluded, the point estimates of the pooled ORs for AKI (1.53) and mortality (1.91) would be comparable to those without the
exclusion (1.92 and 1.41, respectively); however, the effects would no longer be statistically significant.

While this meta-analysis has shown increased risk of AKI because of hyperoncotic HES, randomized trials have demonstrated similar deleterious renal effects in patients receiving iso-oncotic HES [15,16]. Furthermore, in the CRYCO analysis, the incidence of AKI among recipients of iso-oncotic 6% HES 130/0.4 was similar to that of recipients of other evaluated HES solutions.

The present finding of renal protection attributable to hyperoncotic albumin in randomized trials is in contrast to the report of increased AKI in the hyperoncotic albumin group from the CRYCO analysis. Several factors may limit the reliability and generalizability of the CRYCO results with respect to hyperoncotic albumin, namely use of hyperoncotic albumin in a small minority of the most severely ill patients, concomitant infusion of other colloids, absence of a demonstrated dose-response relationship, and exclusion of cirrhotic patients.

No evidence of adverse renal effects was uncovered in a multicenter study of 600 patients receiving 25% albumin [14]. In that observational study, which was specifically designed to evaluate safety, normothermic hypoproteinemic patients at 14 US hospitals received multiple infusions of 80 to 100 mL of 25% albumin over a maximum period of 570 days. Forty-four patients underwent more than 10 infusions each, and the cumulative dose administered to five patients exceeded 800 g. The patients were closely monitored for adverse events, including pyrogenic reactions, anaphylactoid and cardiovascular symptoms, and pulmonary edema. Post-mortem examination of 16 patients who had received 25% albumin doses up to 813 g each showed no evidence of abnormal albumin storage or other renal abnormalities that could not be explained by the disease of which the patients died.

On the basis of the CRYCO findings, recently issued clinical guidelines recommended the avoidance of hyperoncotic dextran, HES, and albumin solutions because of the risk for renal dysfunction [30]. In light of this meta-analysis and the limitations of the CRYCO study, such a blanket recommendation would appear to be unwarranted. A more differentiated approach to the use of these solutions is needed, as recommended in a recent publication [4].

Albumin-mediated renoprotection may be explained by several mechanisms, including maintaining renal perfusion [6,31,32], promoting proximal tubular integrity and function [22,33-38], binding of endogenous toxins and nephrotoxic drugs [39-42], and preventing oxidative

| Study name         | Hyperoncotic colloid, Dead/N | Control, Dead/N | Odds ratio and CI | Odds ratio | Lower limit | Upper limit |
|--------------------|------------------------------|-----------------|-------------------|------------|-------------|-------------|
| Hyperoncotic albumin | Zetterström, Hedstrand 1981  | 0/15            | 1/15              | 0.31       | 0.012       | 8.28        |
|                    | Ginès et al. 1988            | 2/52            | 2/53              | 1.02       | 0.14        | 7.52        |
|                    | Gentilini et al. 1999        | 1/63            | 0/63              | 3.05       | 0.12        | 76.3        |
|                    | Sort et al. 1999             | 14/63           | 26/63             | 0.41       | 0.19        | 0.88        |
|                    | Sola-Vera et al. 2003        | 1/37            | 1/35              | 0.94       | 0.057       | 15.7        |
|                    | Chen et al. 2009             | 4/15            | 6/15              | 0.55       | 0.12        | 2.55        |
| Pooled             | 22/245                       | 36/244          |                   | 0.52       | 0.28        | 0.95        |
| Hyperoncotic HES   | London et al. 1989           | 2/50            | 1/44              | 1.79       | 0.16        | 20.5        |
|                    | Dehne et al. 1997            | 4/10            | 3/15              | 2.67       | 0.45        | 16.0        |
|                    | Brunkhorst et al. 2008       | 107/262         | 93/275            | 1.35       | 0.95        | 1.92        |
|                    | McIntyre et al. 2008         | 9/21            | 6/19              | 1.62       | 0.44        | 5.95        |
| Pooled             | 122/343                      | 103/353         |                   | 1.41       | 1.01        | 1.96        |

Figure 3 Meta-analysis of mortality after hyperoncotic colloid administration. Graphic conventions are the same as in Figure 2. CI, confidence interval; HES, hydroxyethyl starch; N, total number of patients.
damage and binding and delivering protective lysophosphatidic acid [34,36,43,44]. The important renoprotective role of serum albumin was underscored by a recent meta-analysis showing hypoalbuminemia to be a potent independent risk factor both for AKI and for death following the development of AKI [45].

Many medications have been associated with toxic effects on the kidney [46]. Because the kidney receives a quarter of resting cardiac output, glomerular, tubular, and renal interstitial cells can be exposed to substantial concentrations of medications and their metabolites, which can induce changes in kidney structure and function. On the other hand, several mechanisms of HES-induced AKI are reported. HES is degraded and its degradation products are reabsorbed mainly in the proximal tubule. Intracellular accumulation resulting in vacuolization of the proximal tubule may result in functional impairment. Post-mortem examination of 12 patients who received repeated HES 200/0.5 infusions and died after protracted RRT because of ARF showed that the kidney contained the highest tissue concentration of HES compared with any of the other six major organs evaluated [47]. Degradation products of HES are cleared primarily via the kidney. Some of these breakdown products are excreted in the urine, but others can be taken up by the cells of the proximal tubule through pinocytosis. The pinocytic vacuoles subsequently fuse with each other and lysosomes to form larger vacuoles, which can displace other cellular components. HES can accumulate through storage in these oversized lysosomes. There have been no studies published thus far on the type of HES metabolites taken up in the vacuoles and the ability of lysosomal enzymes to degrade them. Vacuolization and swelling of the renal proximal tubular cells are often harbingers of AKI [48].

The histopathologic pattern of acute tubular injury typical of HES accumulation in the kidney is osmotic nephrosis. This phenomenon was first described in 1940 when patients with increased intracranial pressure were treated with intravenous sucrose solutions [48]. Dextran, another colloid composed of glucose units, has also been associated with osmotic nephrosis [1], as have maltose and mannitol [48]. Numerous case reports have documented osmotic nephrosis in patients developing AKI after HES exposure [49-52]. In a randomized trial, HES increased the need for RRT after kidney transplantation, and all biopsied patients receiving HES showed osmotic nephrosis, but none in the control group did [16]. Hydroxyethylation of constituent glucose molecules in the synthesis of HES is specifically intended to retard degradation and prolong action. Osmotic nephrosis resulting from HES exposure can be extremely long-lasting, if not permanent. During long-term follow-up after orthotopic liver transplantation, osmotic nephrosis attributable to HES persisted up to 10 years in 61% of patients [53].

Decreasing levels of renoprotective albumin might be an additional mechanism underlying the nephrotoxicity of HES, which has been shown to cause iatrogenic hypoalbuminemia [54-59]. Inflammatory processes may also contribute to HES-mediated AKI [60]. Further research is needed on pathophysiologic mechanisms as well as on the metabolic fate of HES in the kidney.

Only relatively recently has attention been focused on the possibility that hyperoncotic fluids per se might be injurious to the kidney. Accordingly, the hypotheses tested in the trials of this meta-analysis were not formulated specifically in terms of evaluating a hyperoncotic colloid. Nevertheless, in those trials, patients were randomly allocated to a hyperoncotic colloid or control regimen, and the trials therefore do provide relevant evidence of the renal effects of hyperoncotic colloids. It has recently become increasingly common to discuss ‘hyperoncotic acute renal failure’. This meta-analysis raises doubt that such a concept can satisfactorily account for AKI in patients receiving colloids.

Conclusions
Currently available randomized trial evidence suggests that hyperoncotic albumin solutions may reduce the incidence of AKI and death. The opposite effects appear to be exerted by hyperoncotic HES.

Key messages
• It has been hypothesized that hyperoncotic colloid solutions may damage the kidney. A meta-analysis of randomized controlled trials was performed to test this hypothesis.
• Hyperoncotic albumin decreased the odds of acute kidney injury by 76% and of death by 48%.
• Hyperoncotic hydroxyethyl starch increased the odds of acute kidney injury by 92% and of death by 41%.
• Hyperoncotic colloids per se do not appear to be harmful to the kidney.
• Renal effects may be specific to the particular colloid molecule.

Abbreviations
AKI: acute kidney injury; ARF: acute renal failure; CI: confidence interval; COP: colloid osmotic pressure; CRYCO: Crystalloids or Colloids; HES: hydroxyethyl starch; IQR: interquartile range; OR: odds ratio; RCT: randomized controlled trial; RRT: renal replacement therapy.

Acknowledgements
The authors wish to thank Rajam Csordas-Iyer for critical reading of the manuscript.

Author details
1Department of Internal Medicine, Central Hospital of Bolzano, Lorenz Böhler Street 5, 39100 Bolzano, Italy. 2Department of Internal Medicine I, Medical
References

1. Davidson IJ. Renal impact of fluid management with colloids: a comparative review. Eur J Anaesthesiol 2006, 23:721-738.

2. Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2010, 1.CD007594.

3. Zarychanski R, Turgeon AF, Fergusson DA, Cook DJ, Hébert P, Bagshaw SM, Monsour D, McIntyre L. Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials. Open Med 2009, 3:1169-206.

4. Jarrett ND, Drum M, Forni MG, Greaves E, Noone P, Oudemans-van Straaten HM, Ronco C, Schetz MA, Wurtz AI. Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the working group for nephrology, ESCIM. Intensive Care Med 2010, 36:392-411.

5. Schortgen F, Guiraud F, Deyz N, Brochard L. The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 2008, 34:2157-2168.

6. Baysal C, Ikikawa J, Willis WT, Wilson CB, Brenner BM. Dynamics of glomerular ultrafiltration. IX. Effects of plasma protein concentration. Am J Physiol 1977, 232:F58-71.

7. Hippala S, Linko K, Myllyla G, Lalla M, Makelainen A. Albumin, HES 120 and dextran 70 as adjuncts to red blood cell concentrates: a study on colloid osmotic pressure changes in vitro. Acta Anaesthesiol Scand 1991, 35:659-659.

8. Webb AR, Barclay SA, Bennett ED. In vitro colloid osmotic pressure of commonly used plasma expanders and substrates: a study of the diffusibility of colloid molecules. Intensive Care Med 1989, 15:116-120.

9. Tannesson T, Tallfors T, Kongsgaard UE, Nodeland D. Colloid osmotic pressure of plasma replacement fluids. Acta Anaesthesiol Scand 1993, 37:424-426.

10. Hippala S, Linko K, Myllyla G, Lalla M, Hekal R, Makelainen A. Replacement of major surgical blood loss by hypo-oncotic or conventional plasma substitutes. Acta Anaesthesiol Scand 1995, 39:228-235.

11. Nielsen VG, Baad MS, Brox AE, Matalon S. Extreme, progressive isovolemic hemodilution with 5% human albumin, Pentsalyte, or Hextend does not cause hepatic ischemia or histologic injury in rabbits. Anesthesiology 1990, 90:1428-1435.

12. Cabrera P, Intaglietta M, Tsaia AG. Increase plasma viscosity sustains microcirculation after resuscitation from hemorrhagic shock and continuous bleeding. Shock 2005, 23:549-555.

13. Jacob M, Chappell D, Conzen P, Wilkes MM, Becker BF, Rehm M. Small-volume resuscitation with hyperoncotic albumin: a systematic review of randomized clinical trials. Crit Care 2008, 12:R34.

14. Janeway CA, Gibson ST, Woodruff LM, Heyl JT, Bailey OT, Newhouser LR. Chemical, clinical, and immunological studies on the products of human plasma fractionation. VII. Concentrated human serum albumin. J Clin Invest 1944, 23:465-490.

15. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001, 357:911-916.

16. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Rou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996, 348:1620-1622.

17. Zetterström H, Hedstrand U. Albumin treatment following major surgery. I. Effects on plasma oncotic pressure, renal function and peripheral oedema. Acta Anaesthesiol Scand 1981, 25:125-132.

18. Ginès P, Tito L, Arroyo V, Planas R, Panels J, Viver J, Torres M, Humbert M, Rimala A, Llach J, Badalamenti S, Jimenez W, Gaya J, Rodés J. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. J Hepatol 1993, 19:231-238.

19. Dehne MG, Muhling J, Sablotzki A, Papke G, Kutzschka U, Hempelmann G. Effect of hydroxyethyl starch solution on kidney function in surgical intensive care patients. Anaesthesist Intensivmed Notfallmed Schmerzther 1997, 32:348-354.

20. Gentilini P, Casini-Raggi V, Fiore G, Romagnoli RM, Buzzelli G, Pinzari M, La Villa G, Laffi G. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999, 30:639-645.

21. Port S, Navasa M, Arroyo V, Aldegrever X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Ginès P, Rodés J. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341:403-409.

22. Sola-vera J, Miróa J, Ibarra E, Planella M, González B, Torres X, Rodríguez J, Such J, Pascual S, Soriano G, Pérez-Mateo M, Guarrero C. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003, 37:1157-1163.

23. Brunink FM, Engeli C, Blos F, Meier-Hellmann A, Ragaller M, Wailer N, Moerer O, Grundling M, Oppert M, Grond S, Othoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Leffler M, Reinhart K. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008, 358:132-139.

24. McIntyre LA, Fergusson D, Cook DJ, Rankin N, Dhingra V, Granton J, Magder S, Siehl I, Talaard M, Hebert PC. Fluid resuscitation in the management of early septic shock (FINESS): a randomized controlled feasibility trial. Can J Anaesth 2008, 55:819-826.

25. Chen T-A, Tsao Y-C, Chen A, Lo G-H, Lin C-K, Yu H-C, Cheng L-C, Hsu P-I, Tsai W-C. Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol 2009, 44:619-625.

26. Fernandez J, Montesado J, Barquin A, Jimenez W, Bosch J, Arroyo V, Navasa M. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005, 42:627-636.

27. Wiedermann CJ. Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med 2008, 8:1-8.

28. Brochard L, Abroug F, Brenner M, Broccard AF, Danner RL, Ferrer M, Laghi F, Magder S, Papazian L, Pelosi P, Polderman KH. An Official ATS/ERS/ESICM/SCCM/SRLF Statement: Prevention and Management of Acute Renal
Failure in the ICU Patient: an international consensus conference in intensive care medicine. Am J Respir Crit Care Med 2010, 181:1128-1155.
31. Gerbers JJ. Reproducible vasodilatation by platelet-activating factor in blood- and Krebs-perfused rat kidneys is albumin-dependent. Eur J Pharmacol 1999, 377:119-126.
32. Kaufmann MA, Castelli I, Parger H, Drop LJ. Nitric oxide dose-response study in the isolated perfused rat kidney after inhibition of endothelium-derived relaxing factor synthase: the role of serum albumin. J Pharmacol Exp Ther 1995, 273:853-862.
33. Ott CE, Haas JA, Cuche JL, Knox FG. Effect of increased peritubule protein concentration on proximal tubule reabsorption in the presence and absence of extracellular volume expansion. J Clin Invest 1975, 55:612-620.
34. Levine JS, Koh JS, Traca V, Liebenthal W. Lysophosphatidic acid: a novel growth and survival factor for renal proximal tubular cells. Am J Physiol 1997, 273:F575-585.
35. Dixon R, Brunskill NJ. Activation of mitogenic pathways by albumin in kidney proximal tubule epithelial cells: implications for the pathophysiology of proteinuretic states. J Am Soc Nephrol 1999, 10:1487-1497.
36. Iglesias J, Abernethy VE, Wang Z, Liebenthal W, Koh JS, Levine JS. Albumin is a major serum survival factor for renal tubular cells and macrophages through scavenging of ROS. Am J Physiol 1999, 277:F71-722.
37. Romainelli RC, La Villa G, Barletta G, Vizzutti F, Lanini F, Arena U, Boddi V, Tarquini R, Pantalone P, Gentilini P, Lalli G. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 2006, 12:1403-1407.
38. Lee YJ, Han HJ. Albumin-stimulated DNA synthesis is mediated by Ca²⁺ + PKC as well as EGF receptor-dependent p44/42 MAPK and NF-κB signal pathways in renal proximal tubule cells. Am J Physiol Renal Physiol 2008, 294:F324-541.
39. Contreras AM, Ramirez M, Cueva L, Alvarez S, de Loza R, Gamba G. Low serum albumin and the increased risk of amikacin nephrotoxicity. Rev Invest Clin 1994, 46:43-47.
40. Pockaj BA, Yang JC, Lotze MT, Lange JR, Spencer WF, Steinberg SM, Pockaj BA, Yang JC, Lotze MT, Lange JR, Spencer WF, Steinberg SM. Improvement of hepatorenal syndrome through scavenging of ROS. Am J Physiol 1999, 277:F71-722.
41. Quinlan GJ, Mumby S, Martin GS, Bernard GR, Gutteridge JM, Evans TW. Oxidation of albumin is enhanced in the presence of uremic toxins. J Am Soc Nephrol 1999, 10:1487-1497.
42. Wratten ML, Sereni L, Tetta C. Oxidation of albumin is enhanced in the presence of uricic toxins. Ren Fail 2001, 23:563-571.
43. Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci USA 1987, 84:5918-5922.
44. Quinlan GJ, Mumby S, Martin GS, Bernard GR, Gutteridge JM, Evans TW. Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med 2004, 32:755-759.
45. Wiedermann CJ, Wiedermann W, Joannidis M. Hydroxyethylstarch impairs renal function and induces interstitial proliferation, macrophage infiltration and tubular damage in an isolated renal perfusion model. Crit Care 2009, 13:R23.